A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Conditions
Frontotemporal Dementia · FTD · FTD-GRN · Dementia, Frontotemporal
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio, United States
Vanderbilt University Medical Centre, Nashville, Tennessee, United States
Houston Methodist Hospital, Houston, Texas, United States
UZ Leuven, Leuven, Belgium
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Amsterdam UMC, Amsterdam, Netherlands
NEURO-CARE Sp. z o.o. Sp. Komandytowa, Katowice, Poland
Neurologia Slaska Centrum Medyczne, Katowice, Poland
Uniwersyteckie Centrum Kliniczne, SUM w Katowicach, Katowice, Poland
Euromedis Sp. z o.o., Szczecin, Poland
Centrum Medyczne NeuroProtect Sp z o.o., Warsaw, Poland
Mazowiecki Szpital Brodnowski Sp. z o. o., Warsaw, Poland
Hospital Clinic Barcelona, Barcelona, Spain
Hospital Universitari i Politecnic La Fe, Valencia, Spain
Skåne University Hospital, Lund, Sweden
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
University Hospital of Wales, Cardiff, United Kingdom
University College London Hospitals, London, United Kingdom